The global VEGF inhibitors market, valued at USD 8.45 billion in 2025, is projected to reach USD 15.67 billion by 2034 at a CAGR of 7.8%. Growth is driven by rising cancer and retinal disease prevalence, biologics innovation, and increasing healthcare spending, despite cost and safety challenges.
Read MoreThe global joint pain injections market is growing steadily, driven by rising osteoarthritis prevalence and aging populations. Advancements in biologics and minimally invasive therapies are improving treatment outcomes, while increasing adoption in outpatient settings and emerging markets supports continued market expansion through 2034.
Read MoreThe global intravenous general anesthetics market is growing steadily, driven by rising surgical volumes and advancements in drug formulations. Increasing adoption in ambulatory settings and expanding healthcare infrastructure in emerging markets are supporting demand, despite regulatory challenges and pricing pressures from generic competition
Read More